Antiphospholipid syndrome epidemiology and demographics: Difference between revisions

	Antiphospholipid syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Antiphospholipid syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Antiphospholipid syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Antiphospholipid syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Antiphospholipid syndrome epidemiology and demographics
CDC on Antiphospholipid syndrome epidemiology and demographics
Antiphospholipid syndrome epidemiology and demographics in the news
Blogs on Antiphospholipid syndrome epidemiology and demographics
Directions to Hospitals Treating Antiphospholipid syndrome
Risk calculators and risk factors for Antiphospholipid syndrome epidemiology and demographics

Revision as of 15:23, 22 March 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

APS due to systemic lupus erythermatosus(SLE) is more commonly seen in the African American and Hispanic population.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

@@ Line 20: / Line 20: @@
 ===Age===
-*APS is more common in the elderly age group.
+*The commonly affected age groups are young to middle aged adolescents.
+*However, APS is also seen in children and elderly age group.
 ===Race===
-*APS due to systemic lupus erythermatosus is more commonly seen in the african american population.
+*APS due to systemic lupus erythermatosus(SLE) is more commonly seen in the African American and Hispanic population.
 ===Gender===
-*[Disease name] affects men and women equally.
+*Middle aged women are more commonly affected by APS than males.
-*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 ===Region===
-*The majority of [disease name] cases are reported in [geographical region].
+*There is no particular regional predilection.
 *[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].